25.02.2026
Appointment of a New CSO Completes the Management Board of the medac Group
25.02.2026
Wedel, 25 February 2026 – With the appointment of Dr Christoph Willers as Chief Scientific Officer (CSO), the Management Board of the medac Group has been fully established. Science and Development are being further strengthened as a strategic dimension of corporate leadership, underscoring the scientific foundation and innovative strength of medac.
Clear responsibility for Research, Development and the Pipeline
As CSO, Dr Willers is responsible for Research, Preclinical and Clinical Development, Clinical Studies, as well as Pipeline and Portfolio Management. His mandate is to consistently align research and development with medical needs while further strengthening scientific excellence.
"Scientific quality and clear priorities in research and development are essential for the continued advancement of our company. With Dr Willers, we are strengthening this dimension at Board level as well," says Frank Lucaßen, CEO of the medac Group.
Advancing science and innovation
The CSO role also provides new momentum for the continued development of medac’s scientific foundation. Alongside the ongoing optimisation of existing therapies, there will be an increased focus on new scientific approaches, evidence-based advancements and clinical research. The objective is to drive innovation where it delivers clear medical benefit.
Experience in building and transforming organisations
Dr Willers brings many years of experience in leading scientific organisations, as well as in building and transforming development and manufacturing capabilities. His combination of medical training, scientific expertise and leadership experience provides new perspectives for innovation and responsible development.
With this appointment, medac continues to strengthen its scientific expertise. Step by step, and with the clear ambition of making medically necessary therapies available and improving the quality of life of patients worldwide.